Latest Conference Articles

January 21st 2019, 10:31pm

Gastrointestinal Cancers Symposium (ASCO GI)

Patients with previously untreated hepatocellular carcinoma lived twice as long if they responded to TKI therapy as compared with patients who did not achieve an objective response.

January 21st 2019, 7:48pm

Gastrointestinal Cancers Symposium (ASCO GI)

Jonathan R. Strosberg, MD, discusses the findings from the phase II KEYNOTE-158 trial investigating pembrolizumab in patients with advanced neuroendocrine tumors.

January 21st 2019, 2:08am

SGO Winter Meeting

Robert Coleman, MD, highlights recent advances made in gynecologic cancers and provide insight into ongoing research to move the needle forward.

January 20th 2019, 11:49pm

Gastrointestinal Cancers Symposium (ASCO GI)

The combination use of durvalumab and tremelimumab plus best supportive care prolonged median overall survival by 2.5 months compared with supportive care alone in patients with advanced refractory colorectal cancer.

January 20th 2019, 9:15pm

Gastrointestinal Cancers Symposium (ASCO GI)

The PD-L1 inhibitor durvalumab achieved objective responses in about a fourth of patients with microsatellite instability-high advanced solid tumors, including colorectal cancer.

January 20th 2019, 2:15pm

SGO Winter Meeting

Charles A. Leath III, MD, gyn oncologist at the University of Alabama at Birmingham, discusses the glaring unmet need in cervical cancer.

January 20th 2019, 1:29pm

SGO Winter Meeting

Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses advances made in the treatment of ovarian cancer.

January 20th 2019, 6:04am

Gastrointestinal Cancers Symposium (ASCO GI)

Clinical outcomes with the combination of encorafenib, binimetinib, and cetuximab exceed historic data in patients with BRAF V600E-mutant metastatic colorectal cancer.

January 20th 2019, 5:58am

SGO Winter Meeting

For all the positive data associated with PARP inhibitors in patients with epithelial ovarian cancer who have known BRCA mutations and despite several agents winning FDA approval over the past few years, PARP inhibitors aren’t curing patients.

January 20th 2019, 12:28am

Gastrointestinal Cancers Symposium (ASCO GI)

The oral multi-kinase inhibitor regorafenib extended progression-free survival in patients with metastatic or unresectable biliary tract cancer who were previously treated with gemcitabine and a platinum-based chemotherapy.

January 19th 2019, 11:29pm

SGO Winter Meeting

Shannon Westin, MD, discusses the evolving role of PARP inhibitors in ovarian cancer, novel investigational agents, and the importance of molecular testing.

January 19th 2019, 10:49pm

Gastrointestinal Cancers Symposium (ASCO GI)

Josep M. Llovet, MD, PhD, discusses the results from the phase III REACH-2 study of ramucirumab as a second-line treatment of patients with advanced hepatocellular carcinoma.

January 19th 2019, 9:13pm

Gastrointestinal Cancers Symposium (ASCO GI)

The combination of dabrafenib and trametinib induced responses in nearly half of patients with BRAF V600E–mutated biliary tract cancer who participated in a phase II basket trial that enrolled patients with BRAF V600E–mutated rare cancers.

January 19th 2019, 8:13pm

Gastrointestinal Cancers Symposium (ASCO GI)

The novel oral anticancer regimen known as SM-88, which consists of a tyrosine derivative, an mTOR inhibitor, a CYP3a4 inducer, and an oxidative stress catalyst, has promising efficacy with no meaningful toxicity in patients with metastatic pancreatic cancer who have progressed on at least 1 prior line of therapy.

January 19th 2019, 11:40am

SGO Winter Meeting

Adria Suarez Mora, MD, second-year fellow at UPMC Magee-Womens Hospital, discusses how sequential sampling of intraperitoneal fluid during chemotherapy help better define the immunogenic effects of the treatment.

January 19th 2019, 10:19am

SGO Winter Meeting

Kathleen G. Essel, MD, gynecologic oncology fellow at the University of Oklahoma Health Science Center with the Stephenson Cancer Center, discusses the benefits of using quantitative computed tomography image feature analysis to predict response to immune checkpoint inhibitors in patients with gynecologic cancers.

January 19th 2019, 5:55am

SGO Winter Meeting

Carolyn Lefkowits, MD, gynecologic oncologist, and palliative care doctor, at the University of Colorado, addresses common misconceptions regarding palliative care integration.

January 19th 2019, 3:33am

SGO Winter Meeting

Targeted therapy is effectively established as an option for patients with ovarian cancers. However, beyond PARP inhibition in the BRCA-mutated or homologous recombination deficient population, questions remain about how to best treat these patients.

January 19th 2019, 3:28am

Gastrointestinal Cancers Symposium (ASCO GI)

Daniela Molena, MD, discusses what she believes is the Achilles heel of endoscopic resection in patients with esophageal cancer.

January 19th 2019, 3:22am

SGO Winter Meeting

The prognosis for women with recurrent or metastatic cervical cancer after treatment failure is notoriously poor, but immunotherapy agents may offer longer survival for this population.